<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30147088</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1998-4774</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>55</Volume>                    <Issue>1</Issue>                    <PubDate>                        <MedlineDate>2018 Jan-Mar</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Indian journal of cancer</Title>                <ISOAbbreviation>Indian J Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis.</ArticleTitle>            <Pagination>                <MedlinePgn>16-22</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/ijc.IJC_484_17</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Survival studies may serve as benchmarks to develop cancer-related policies and estimate baseline survival rates in a given patient population.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">We carried out a retrospective audit of cases managed in 2009 and now report the disease-free survival (DFS) in early breast cancer (EBC) and locally advanced breast cancer (LABC) in patients registered at a tertiary cancer center in India.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The study included 2192 patients with breast cancer with ages ranging from 18 years to 94 years with a median of 50 years. Of these, 888 (40.5%) were EBCs Stage I and II, 833 (38%) were LABCs (Stage III), and 471 (21.5%) were de novo metastatic or relapsed cancers at presentation. The 5-year DFS in the women with EBC was 85.5% and in LABC, it was 67.7%, P &lt; 0.001. The factors adversely affecting DFS in EBC were node metastasis (P &lt; 0.001), higher metastatic nodes (P &lt; 0.001), hormone receptor negativity (P = 0.001), and human epidermal growth factor receptor 2 (Her2neu) positivity (P = 0.033). In the multivariate Cox regression analysis in EBC, node-positive status (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.51-3.45, P &lt; 0.001) and hormone receptor negative tumors (HR 1.96, 95% CI 1.30-2.94, P = 0.001) significantly affected DFS in EBC. The factors adversely affecting DFS in LABC in the univariate analysis were node metastasis (P &lt; 0.001), increasing numbers of nodes (P &lt; 0.001), presence of lymphovascular emboli (LVE) (P &lt; 0.01), mastectomy (P &lt; 0.001), and Her2neu positivity (P = 0.03). In the multivariate Cox regression analysis, node positivity (HR 2.96, 95% CI 2.04-4.29, P &lt; 0.0001), presence of LVE (HR 1.47, 95% CI 1.06-2.04, P = 0.023), and mastectomy (HR 1.49, 95% CI 1.06-2.10, P = 0.023) adversely impacted DFS in LABC.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">The survival rates in this study are equal to the documented global rates; nodal disease burden emerged as the most important prognostic factor. In addition, in EBCs, a lack of hormone receptor expression and in LABC, Her2neu overexpression appear to worsen the outcome.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nair</LastName>                    <ForeName>Nita</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shet</LastName>                    <ForeName>Tanuja</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Parmar</LastName>                    <ForeName>Vani</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Havaldar</LastName>                    <ForeName>Rohini</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Research Secretariat, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gupta</LastName>                    <ForeName>Sudeep</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Budrukkar</LastName>                    <ForeName>Ashwini</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarin</LastName>                    <ForeName>Rajiv</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>I/C Cancer Genetic Unit, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thakur</LastName>                    <ForeName>Meenakshi</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Desai</LastName>                    <ForeName>Sangeeta</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yadav</LastName>                    <ForeName>Prabha</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jalali</LastName>                    <ForeName>Rakesh</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gulia</LastName>                    <ForeName>Seema</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wadasadawala</LastName>                    <ForeName>Tabassum</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gosh</LastName>                    <ForeName>Jaya</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bajpai</LastName>                    <ForeName>Jyoti</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kembhavi</LastName>                    <ForeName>Seema</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Patil</LastName>                    <ForeName>Asawari</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Joshi</LastName>                    <ForeName>Shalaka</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Popat</LastName>                    <ForeName>Palak</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rangarajan</LastName>                    <ForeName>Venkatesh</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shah</LastName>                    <ForeName>Sneha</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vanmali</LastName>                    <ForeName>Vaibhav</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Research Secretariat, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siddiqui</LastName>                    <ForeName>Shabina</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Research Secretariat, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mittra</LastName>                    <ForeName>Indraneel</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Badwe</LastName>                    <ForeName>Rajendra</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>Indian J Cancer</MedlineTA>            <NlmUniqueID>0112040</NlmUniqueID>            <ISSNLinking>0019-509X</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">India</Keyword>            <Keyword MajorTopicYN="N">survival</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30147088</ArticleId>            <ArticleId IdType="pii">IndianJournalofCancer_2018_55_1_16_239598</ArticleId>            <ArticleId IdType="doi">10.4103/ijc.IJC_484_17</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>